/Companies

Neurofenix London

Entrepreneur First '16

London, GB · Founded 2016 · 6 employees on LinkedIn · 4 known investors

Find your way into Neurofenix London

Each arrow is one introduction. Sign up to fill in the first one.

1,243 people can intro you to Guillem

Ask Boris Ploix to introduce you to Guillem Buxarrais

You →Boris · together at EF LON6 →Guillem

1,099 people can intro you to Dimitris

Ask Jamie Chen to introduce you to Dimitris Athanasiou

You →Jamie · together at Lightpointmedical →Dimitris

Sign up to find every way you can get introduced to Neurofenix London

  • Your email: who you already know at Neurofenix London, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Neurofenix London team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Neurofenix develops neuro-rehabilitation technology and delivers virtual in-home therapy services for people recovering from neurological conditions such as stroke. Its offering combines occupational and clinical therapy with its own rehabilitation platform.

Also known as Neurofenix

Founders & leadership

Neurofenix London was founded in 2016 by Guillem Buxarrais and Dimitris Athanasiou.

GBGuillem Buxarrais
Guillem BuxarraisCo-founder and Chief Executive Officer2016–2025Guillem Buxarrais brings 12 years of healthcare strategy experience and serves as CEO of Neurofenix London, which provides technology-enabled neurorehabilitation therapy to patients at home. Previously, he co-founded and led Neurofenix to partnerships with 40+ health systems and academic medical centers, contributed to peer-reviewed publications on the therapy, and led the sale of the company's technology to Bioness Medical.
DADimitris Athanasiou
Dimitris AthanasiouCo-founder - Chief Product & Technology Officer2016–2025Dimitris Athanasiou is cofounder and product lead at Neurofenix, where he has spent nearly a decade developing an FDA-registered neurorehabilitation platform and overseeing product, technology, R&D, regulatory approvals, and clinical trials. He studied at Imperial College London and the National Technical University of Athens.

Investors · 4

Company profile

researched Aug 2026

Neurofenix is a virtual care provider focused on neurological rehabilitation delivered in patients' homes. Its model pairs each patient with a dedicated therapist and an expert clinical team, who design personalized weekly therapy plans intended to deliver high-dose, high-repetition, high-intensity full-body therapy. The company positions its approach as grounded in neuroplasticity principles, using gamified therapy sessions, remote monitoring and messaging to sustain patient engagement and habit formation between sessions.

A flagship offering is an Upper Limb Stroke Program aimed at stroke survivors and their caregivers, referenced on the company website alongside the NeuroBall device mentioned in patient testimonials. Supporting technology includes remote tracking devices that report real-time usage data and the NeuroPlatform and accompanying dashboard, which clinicians use to monitor patient progress. The company states that it produces HIPAA-compliant reports, evaluations and monitoring outputs to support clinical decision-making and documentation.

Neurofenix markets itself to healthcare organizations as an extension of existing care pathways, offering same-day patient enrollment, updates on enrollment status and progress, and a 24/7 contact line (1-800-945-8132). The website references accreditations and collaborations without detailing them in the retrieved material.

Business model

Neurofenix delivers therapy services virtually, combining clinician labor (a dedicated therapist and clinical team) with proprietary hardware and software. It invites healthcare providers to partner with it to add virtual care services for their neurological patients, while also addressing stroke survivors and caregivers directly.

Traction

Evidence in the retrieved sources is limited to patient testimonials on the company website describing functional gains such as improved use of the hand and arm and greater training duration. No user counts, revenue, contract or outcome statistics are disclosed.

Latest developments

No dated news, funding or product announcements about Neurofenix appear in the retrieved sources; the only company-specific material is its current website.

▸Full profile — market position, technology, go-to-market, geography

Market position

The company frames its market opportunity around access gaps, stating that 70% of Americans lack access to neuro rehabilitation because of factors such as few locations, transportation, high out-of-pocket costs, long waitlists and cultural barriers, and positions its virtual care model as removing those barriers. The retrieved sources contain no competitive comparisons or market-share data.

Technology

The stack comprises remote tracking devices that stream real-time usage data, gamified therapeutic activities performed at home (patient testimonials cite the NeuroBall for hand and arm movement), and the NeuroPlatform with a monitoring dashboard used to track patient progress. Outputs include HIPAA-compliant reports, evaluations and monitoring records, and the company says its approach integrates with existing healthcare systems and care pathways.

Go-to-market

Two-sided outreach: a partnership motion toward clinicians and healthcare organizations that can refer neurological patients, supported by same-day enrollment, progress reporting and a 24/7 contact line; and a direct-to-patient motion addressing stroke survivors and caregivers through the website, testimonials and 'let's talk' contact prompts.

Neurological patients rehabilitating at home, particularly stroke survivors and their caregivers, and the healthcare providers and organizations that refer or manage such patients and wish to extend rehabilitation services into the home.

Geography

Internal records place the headquarters in London, United Kingdom. Public-facing material is US-oriented, citing a US toll-free contact number, HIPAA-compliant documentation and access statistics for Americans.

Compiled by commissioned research from 3 cited public sources — announcements, filings, and press listed under research sources below.

Key figures

latest reported
Share of Americans without access to neuro rehab (company-stated addressable proJan 202570%

Company-reported or press-reported figures, each dated to when it was claimed — not independently audited.

▸Research sources · 3

primary sources listed

3 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Neurofenix London do?
Neurofenix is a tech-enabled virtual care provider delivering at-home neurological rehabilitation with dedicated therapists.
Who founded Neurofenix London?
Neurofenix London was founded by Guillem Buxarrais, Dimitris Athanasiou in 2016.
Who are Neurofenix London's investors?
Neurofenix London's investors include AlbionVC, Entrepreneur First, InHealth Ventures, Oxford Investment Opportunity Network (OION).
Where is Neurofenix London headquartered?
Neurofenix London is headquartered in London, GB.